Searched for
BICARA THERAPEUTICS
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- 'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...
- Kiran Mazumdar-Shaw picks niece Claire as successor at BioconBiocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The t...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successorBiocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the comp...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- Meet Kiran Mazumdar-Shaw's niece Claire: An MIT grad making Indian innovation shine with $1 billion market debutClaire Mazumdar, CEO of Bicara Therapeutics and niece of Kiran Mazumdar-Shaw, led her company to a successful Nasdaq debut, reaching a mark...
- With IPO, have the capital and resources for clinical studies: Bicara CEOAs per Reuters, shares of Bicara Therapeutics surged nearly 46% in their debut on September 13, giving the TPG-backed cancer therapy develo...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Footpath Ventures eyes stake in Rajasthan Royals; IT hiring picks upUS-based Footpath Ventures is in advanced talks to pick up a stake in Rajasthan Royals, a franchise in the Indian Premier League (IPL). Thi...
- Udaan's fundraise; VC-backed listed tech firms hit $50B market capBusiness-to-business (B2B) ecommerce firm Udaan has raised $340 million through conversion of its debt and fresh equity infusion. This and ...
- Cancer therapy firm Bicara raises $165 millionBicara, founded in 2020 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company currently developing dual-action b...
- Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw“Trastuzumab (monoclonal antibody used to treat breast and stomach cancers) is another big opportunity we are looking at, not just in the U...
- Biocon Q1 results: Profit dips on losses at US subsidiary Bicara, revenue grows by 6%Before accounting for the loss at Bicara, a personal therapeutic company, Biocon's profits stood at Rs 142 crore.
- Biocon Q4 results: Net profit grows 105% on strong biosimilar business growthFor the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...
- Stock pick of week: Biocon is on fast track to growth, making it analysts' top betStrong annual results for 2018-19 including improvement in net profit, growth momentum in its biosimilars business and recent price correct...
Load More
